Table 2.
ADC drugs approved for hematologic malignancies [49].
| ADC | Manufacturers | Approval Years | Targets | Payloads | Indications |
|---|---|---|---|---|---|
| Adcetris (brentuximab vedotin) | Seagen | 2011 | CD30 | Monomethyl auristatin E (MMAE) | Adults with classical Hodgkin’s lymphoma (CHL) in stages 3 and 4 without prior treatment history Pediatric patients aged 2 and above with high-risk classical Hodgkin’s lymphoma (CHL) and no previous treatment history Adult patients with systemic anaplastic large cell lymphoma (ALCL) without a history of prior treatment Adult patients with primary cutaneous anaplastic large cell lymphoma |
| Blenrep (belantamab mafodotin) | GSK | 2020 | BCMA | Monomethyl auristatin F | Adult patients with relapsed or refractory multiple myeloma who have received the selected treatment at least four times |
| Besponsa (inotuzumab ozogamicin) | Pfizer | 2017 | CD22 | Calicheacmicin | Monotherapy for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults |
| Mylotarg (gemtuzumab ozogamicin) | Pfizer | 2000; 2017 | CD33 | Calicheacmicin | Monotherapy and combination therapy (up to 2 years) for newly diagnosed CD33-positive AML in adults and relapsed or refractory CD33-positive AML in both adults and pediatric patients |
| Polivy (polatuzumab vedotin) |
Genentech | 2019 | CD79b | MMAE | Combination therapy with bendamustine and rituximab in adult patients with relapsed or refractory indolent B-cell lymphoma |
| Zynlonta (loncastuximab tesirine) | ADC Therapeutics | 2021 | CD19 | SG3249 PBD dimer | Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low-grade lymphoma and high-grade B-cell lymphoma, after two or more systemic therapies, not otherwise specified |